comparemela.com
Home
Live Updates
Arbutus Biopharma : Preliminary Data Shows that Arbutus Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity - Form 8-K : comparemela.com
Arbutus Biopharma : Preliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity - Form 8-K
Preliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
WARMINSTER, Pa., Dec. 01, 2021 --... | December 1, 2021
Related Keywords
United States ,
Canada ,
Canadian ,
Gaston Picchio ,
Lisam Caperelli ,
Williamh Collier ,
Arbutus Biopharma Corporation Nasdaq ,
World Health Organization ,
Securities Exchange ,
Preliminary Data Shows ,
Arbutu Capsid Inhibitor ,
Generally Safe ,
Provides Robust Antiviral ,
Biopharma Corporation ,
Chief Development Officer ,
Looking Statements ,
Securities Act ,
Securities Exchange Act ,
Arbutu Annual Report ,
Arbutu Quarterly Reports ,
Arbutus Biopharma Corporation Stock Exchange ,
News ,
Information ,
Press Release ,
Reliminary ,
Data ,
Shows ,
Hat ,
Capsid ,
Us ,
Igenerally ,
Safe ,
End ,
Rovides ,
Obust ,
Antiviral ,
021 Abus Ca03879j1003 ,
comparemela.com © 2020. All Rights Reserved.